Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis

Molecular Medicine

Volumn 13, Issue 3-4, 2007, Pages 210-215

  Goldstein, Richard S ^a,b   Bruchfeld, Annette ^a,c   Yang, Lihong ^a   Qureshi, Abdul R ^c   Gallowitsch Puerta, Margot ^a   Patel, Nirav B ^a   Huston, Brett J ^a   Chavan, Sangeeta ^a   Rosas Ballina, Mauricio ^a   Gregersen, Peter K ^a   Czura, Christopher J ^a   Sloan, Richard P ^d   Sama, Andrew E ^a,b   Tracey, Kevin J ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGED; ARTICLE; CHOLINERGIC STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART RATE VARIABILITY; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RR INTERVAL; VAGUS TONE;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLINERGIC AGENTS; FEMALE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VAGUS NERVE;

EID: 34250620898     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2006-00108.Goldstein     Document Type: Article

References (28)

1. Kvien TK. (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics.22:1-12.
2. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. (2005) Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology. 44:1169-75.
3. Kvien TK, Uhlig T, Odegard S, Heiberg MS. (2006) Epidemiological aspects of rheumatoid arthritis; the sex ratio. Ann. N. Y. Acad. Sci. 1069:212-22.
4. Mutru O, Laakso M, Isomaki H, Koota K. (1985) Ten year mortality and causes of death in patients with rheumatoid arthritis. Br. Med. J. 290:1797-9.
5. Kokkola R et al. (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 48:2052-8.
6. Taniguchi N et al. (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48:971-81.
7. Pullerits R et al. (2003) High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48:1693-700.
8. Andersson U, Tracey KJ. (2004) HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum. Dis. Clin. North Am. 30:627-37.
9. Lotze MT, Tracey KJ. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5:331-42.
10. Wang H et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-51.
11. Tracey KJ. (2002) The inflammatory reflex. Nature. 420:853-9.
12. Borovikova LV et al. (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 405:458-62.
13. Wang H et al. (2003) Nicotinic acetylcholine receptor α7 receptor is an essential regulator of inflammation. Nature. 421:384-8.
14. Bernik TR et al. (2002) Pharmacological stimulation of the cholinergic anti-inflammatory pathway. J. Exp. Med. 195:781-8.
15. Wang H et al. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10:1216-21.
16. Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. (2003) The cholinergic anti-inflammatory pathway: a missing link in neuromodulation. Mol. Med. 9:125-34.
17. Arnett FC et al. (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-24.
18. Fransen J, Stucki G, van Riel P. (2003) Rheumatoid arthritis measures. Arthritis Rheum. 49:S214-24.
19. (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 93:1043-65.
20. Song HS, Lehrer PM. (2003) The effects of specific respiratory rates on heart rate and heart rate variability. Appl. Psychophysiol. Biofeedback. 28:13-23.
21. Akselrod S et al. (1981) Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 213:220-2.
22. Pomeranz B et al. (1985) Assessment of autonomic function in humans by heart rate spectral analysis. Am. J. Physiol. 248:151-3.
23. Saul JP et al. (1991) Transfer function analysis of the circulation: unique insights into cardiovascular regulation. Am. J. Physiol. 261:1231-45.
24. Taylor JA, Carr DL, Myers CW, Eckberg DL. (1998) Mechanisms underlying very-low-frequency RR-interval oscillations in humans. Circulation 98:547-55.
25. Evrengul H et al. (2004) Heart rate variability in patients with rheumatoid arthritis. Rheumatol. Int. 24:198-202.
26. Louthrenoo W, Ruttanaumpawan P, Aramrattana A, Sukitawut W. (1999) Cardiovascular autonomic nervous system dysfunction in patients with rheumatoid arthritis and systemic lupus erythematosus. QJM. 92:97-102.
27. Gonzalez-Juanatey C et al. (2003) Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine. 82:407-13.
28. Park YB et al. (2002) Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 46:1714-9.